6946-14-1

Usage

Uses

Used in Pharmaceutical Research:
3-Acetamido-4-methylbenzoic acid is used as a building block in pharmaceutical research for the synthesis of various pharmaceuticals and bioactive molecules. Its unique chemical structure allows for the creation of compounds with potential therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Acetamido-4-methylbenzoic acid is utilized as a key intermediate for the preparation of complex organic compounds, contributing to the advancement of chemical science and technology.
Used in Anti-inflammatory and Analgesic Applications:
3-Acetamido-4-methylbenzoic acid is studied for its potential anti-inflammatory and analgesic properties, making it a candidate for the development of new medications aimed at treating pain and inflammation.
Used in Chemical Safety:
Proper handling and storage of 3-Acetamido-4-methylbenzoic acid are essential due to its chemical nature, ensuring safety in research and industrial applications. It should be managed in accordance with established chemical safety guidelines to prevent any adverse effects.

InChI:InChI=1/C10H11NO3/c1-6-3-4-8(10(13)14)5-9(6)11-7(2)12/h3-5H,1-2H3,(H,11,12)(H,13,14)

Upstream product

• 2458-12-0 3-amino-p-toluic acid 
• 108-24-7 acetic anhydride 
• 127506-01-8 C₁₁H₁₃NO₃ 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 81018-31-7 3-acetylamino-4-methyl-benzonitrile 
• 60710-80-7 5-cyano-2-methylaniline 
• 120-66-1 N-(2-methylphenyl)acetamide 
• 67-64-1 acetone 
• 861525-09-9 acetic acid-(5-chloroacetyl-2-methyl-anilide) 
• 103151-16-2 3-acetylamino-4-methyl-benzoic acid amide 

Downstream Products

• 2458-12-0 3-amino-p-toluic acid 
• 37901-90-9 3-amino-4-methyl-2-nitrobenzoic acid 
• 926037-48-1 Radotinib 
• 641571-10-0 nilotinib 
• 7356-52-7 3-acetylamino-4-methyl-2-nitrobenzoic acid 
• 320740-32-7 3-bromo-4-methyl-2-nitrobenzoic acid 
• 320740-33-8 methyl 3-bromo-4-methyl-2-nitrobenzoate 
• 320740-35-0 2-amino-3-bromo-4-methylbenzoic acid 
• 320740-34-9 methyl 2-amino-3-bromo-4-methylbenzoate 

Relevant academic research and scientific papers

COVALENT INHIBITORS OF KRAS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a,

NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).

The synthesis of C2-symmetric and axially chiral compounds for recognition and catalysis

Axially chiral amidines and guanidines, some possessing C2-symmetry, have been targeted as potential chiral catalysts for reactions of α,β-unsaturated carboxylic acids or esters. The key step in each synthesis required the coupling of two sterically demanding aromatic compounds to form atropisomeric biaryl species. (C) 2000 Elsevier Science Ltd.